We are happy to report that the oppositions filed by our client betapharm and eight other generics manufacturers against Novartis patent EP 3 351 246 were successful; the Board of Appeal of the European Patent Office revoked the Novartis patent for lack of inventive step (file number: T0814/22-3.3.07).
In reaction to this decision, Novartis also withdrew its parallel infringement action against our client betapharm that was pending before the Düsseldorf Appeal Court.
The full text version of the JUVE Patent communication can be found here.
